Ebi Rowshanshad
Family Medicine · Los Angeles, CANPI 1518469790
Payments from drug & device makers
Across 178 payments — averaging $16.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$881
- Lilly USA, LLC$339
- AbbVie$310
- Otsuka America Pharmaceutical, Inc.$166
- Abbott$126
- Amgen$115
- plus $960 from 19 others
What the payments were for
- Food & beverage$2,80297%
- Education$442%
- Other$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 68 | $881 |
| Lilly USA, LLC | 24 | $339 |
| AbbVie | 16 | $310 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Abbott | 4 | $126 |
| Amgen | 7 | $115 |
| Boehringer Ingelheim | 6 | $114 |
| Exact Sciences | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $92 |
| GSK | 4 | $84 |
| Lundbeck LLC | 3 | $79 |
| Pfizer | 5 | $74 |
| AstraZeneca | 4 | $68 |
| Merz North America, Inc. | 2 | $66 |
| Verona Pharma, Inc. | 3 | $54 |
| Shield Therapeutics Inc | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Noven Therapeutics, LLC | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Medtronic | 1 | $12 |
How this compares
$2,896 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $84,108 |
| EliquisApixaban | 56 | $48,411 |
| JardianceEmpagliflozin | 43 | $44,885 |
| WegovySemaglutide | 32 | $41,586 |
| MounjaroTirzepatide | 28 | $40,793 |
| TrulicityDulaglutide | 29 | $30,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $24,088 |
| FarxigaDapagliflozin Propanediol | 14 | $22,095 |
| TrintellixVortioxetine Hydrobromide | 19 | $16,757 |
| JanuviaSitagliptin Phosphate | 12 | $14,433 |
| EntrestoSacubitril/Valsartan | 14 | $14,386 |
| RybelsusSemaglutide | 12 | $12,357 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $10,941 |
| Repatha SureclickEvolocumab | 13 | $10,396 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $881 | $138,051108 claims |
| Lilly USA, LLCMounjaro, Trulicity | $339 | $71,13257 claims |
| PfizerEliquis | $74 | $48,41156 claims |
| Boehringer IngelheimJardiance | $114 | $44,88543 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $84 | $35,02849 claims |
| AstraZenecaFarxiga | $68 | $22,09514 claims |
| MerckJanuvia | $15 | $14,43312 claims |
| AbbVieSynthroid | $310 | $1,14222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Los Angeles
- Albert NassirLos Angeles$5.7M
- Nader SobhLos Angeles$4.1M
- Alexander RivkinLos Angeles$2.8M
- Pamela KushnerLos Angeles$1.2M
- Scott HowellLos Angeles$793K
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.